Amendments to the Claims:

This listing of claims will replace all prior versions, and listings, of claims in the application:

1. (Original) Solid dispersions comprising a pooly soluble bioactive compound dispersed in a polymer matrix, comprising more than one polymer, characterized in that a first polymer allows a homogenous or molecular dispersion of the bioactive compound in the polymer matrix, while a second polymer has a dissolution profile associated with the creation of a micro-environment enhancing the dissolution of the bioactive compound in an aqueous environment.

2. (Original) Solid dispersions according to claim 1 characterized in that the polymer matrix comprises a polymer having a stabilizing effect on the bioactive compound in solution.

3. (Currently Amended) Solid dispersions according to claim 1 ~~claims 1 or 2~~ wherein the polymer allowing a homogenous dispersion is PVPVA64.

4. (Currently Amended) Solid dispersions according to claim 1 ~~claims 1 to 3~~ wherein the polymer allowing enhanced dissolution of the bioactive compound in an aqueous environment is Eudragit E100.

5. (Currently Amended) Solid dispersions according to claim 1 ~~claims 1 or 2~~ wherein the polymer allowing enhanced dissolution of the bioactive compound in an aqueous environment is hydroxyl-propyl methyl cellulose.

6. (Currently Amended) Solid dispersions according to claim 1 ~~claims 1 to 2~~ wherein the polymer matrix comprises Eudragit E100 and PVPVA64.

7. (Original) Solid dispersions according to claim 6 wherein a Eudragit E100/PVPVA64 ration varies between 70/30 and 80/20.

8. (Currently Amended) Solid dispersions according to claim 1 ~~claims 1 to 2~~ wherein the polymer matrix comprises hydroxyl-propyl methyl cellulose and PVPVA64.

9. (Currently Amended) Solid dispersions according to claim 1 ~~to 8~~ enhancing the bioavailability o an orally administered bioactive compound.

10. (Currently Amended) Solid dispersions according to claim 1 ~~claims 1 to 9~~ wherein the bioactive compound is a class II drug in the Biopharmaceutical Classification System.

11. (Currently Amended) Solid dispersions according to claim 1 ~~claims 1 to 9~~ wherein the bioactive compound is a class IV drug in the Biopharmaceutical Classification System.

12.. (Currently Amended) Solid dispersions according to claim 1 ~~to 11~~ wherein the aqueous environment is a gastro-intestinal fluid.

13. (Original) Solid dispersions according to claim 12 wherein the aqueous environment is a gastric fluid.

14. (Currently Amended) Solid dispersions according to claim 1 ~~any of the claims 1 to 13~~ prepared by extrusion.

15. (Currently Amended) Solid dispersion according to claim 1 ~~any of the claims 1 to 13~~ prepared by spray-drying.